Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -5.68% | -48.49% | -49.06% | -23.84% | -67.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.68% | -48.49% | -49.06% | -23.84% | -67.01% |
| Cost of Revenue | -60.95% | -68.05% | -24.25% | -24.12% | -61.47% |
| Gross Profit | 4.65% | -45.38% | -52.03% | -23.75% | -67.87% |
| SG&A Expenses | -22.69% | -23.13% | -9.81% | -11.49% | -29.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.71% | -20.29% | -22.32% | -25.03% | -21.47% |
| Operating Income | 46.52% | 1.33% | 9.34% | 25.59% | -56.13% |
| Income Before Tax | 43.76% | -6.95% | 8.51% | 24.54% | -29.19% |
| Income Tax Expenses | -27,200.00% | 145.23% | -190.91% | -97.85% | 100.27% |
| Earnings from Continuing Operations | 44.13% | -7.76% | 8.70% | 24.91% | -30.05% |
| Earnings from Discontinued Operations | -- | 249.32% | 14.63% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.25% | 22.54% | 9.20% | 24.91% | -43.18% |
| EBIT | 46.52% | 1.33% | 9.34% | 25.59% | -56.13% |
| EBITDA | 50.33% | -4.37% | 7.82% | 26.57% | -48.93% |
| EPS Basic | 55.86% | 31.57% | 17.32% | 29.20% | -34.44% |
| Normalized Basic EPS | 53.31% | 3.74% | 13.78% | 31.90% | -79.58% |
| EPS Diluted | 55.86% | 31.57% | 17.32% | 28.97% | -34.39% |
| Normalized Diluted EPS | 53.31% | 3.74% | 13.78% | 31.90% | -79.58% |
| Average Basic Shares Outstanding | 14.98% | 13.19% | 9.81% | 6.07% | 6.50% |
| Average Diluted Shares Outstanding | 14.98% | 13.19% | 9.81% | 6.07% | 6.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |